[
  {
    "ts": null,
    "headline": "Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight",
    "summary": "The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.",
    "url": "https://finnhub.io/api/news?id=6fdd21760a3d9cddf4caa3409f50674a1cbfac444dcdba2abccc6b56310ee9cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765492260,
      "headline": "Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight",
      "id": 137766873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.",
      "url": "https://finnhub.io/api/news?id=6fdd21760a3d9cddf4caa3409f50674a1cbfac444dcdba2abccc6b56310ee9cd"
    }
  },
  {
    "ts": null,
    "headline": "Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment",
    "summary": "Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, the company delivered promising Pivotal Phase 2 study results of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. The company is developing an anti-CD in partnership with Kite, a Gilead company unit, […]",
    "url": "https://finnhub.io/api/news?id=f47e16e696702f53cc59bebfaf9975dd15e989f79ea58ee0930dd2fb42d112da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765457062,
      "headline": "Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment",
      "id": 137757021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, the company delivered promising Pivotal Phase 2 study results of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. The company is developing an anti-CD in partnership with Kite, a Gilead company unit, […]",
      "url": "https://finnhub.io/api/news?id=f47e16e696702f53cc59bebfaf9975dd15e989f79ea58ee0930dd2fb42d112da"
    }
  },
  {
    "ts": null,
    "headline": "3 Profitable Stocks We Keep Off Our Radar",
    "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, \"Your margin is my opportunity\".",
    "url": "https://finnhub.io/api/news?id=f24ce79380ac5b2626b692e43730d2ab79acc207508c72b6f2634d486f329c90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765427761,
      "headline": "3 Profitable Stocks We Keep Off Our Radar",
      "id": 137758013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, \"Your margin is my opportunity\".",
      "url": "https://finnhub.io/api/news?id=f24ce79380ac5b2626b692e43730d2ab79acc207508c72b6f2634d486f329c90"
    }
  }
]